InflaRx (NASDAQ:IFRX) Sees Significant Growth in Short Interest

InflaRx (NASDAQ:IFRX - Get Free Report) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 564,700 shares, a growth of 46.2% from the February 13th total of 386,300 shares. Currently, 1.0% of the company's stock are sold short. Based on an average daily volume of 382,600 shares, the days-to-cover ratio is currently 1.5 days.

InflaRx Stock Performance

Shares of NASDAQ:IFRX traded up $0.08 during trading hours on Wednesday, reaching $1.29. The stock had a trading volume of 403,908 shares, compared to its average volume of 216,148. The stock has a market capitalization of $86.74 million, a price-to-earnings ratio of -1.21 and a beta of 1.98. The firm's 50 day moving average is $1.98 and its 200-day moving average is $1.91. InflaRx has a 1 year low of $1.13 and a 1 year high of $2.82.

Institutional Trading of InflaRx

Large investors have recently made changes to their positions in the company. Raymond James Financial Inc. purchased a new stake in InflaRx in the fourth quarter valued at approximately $1,576,000. Northern Trust Corp increased its holdings in shares of InflaRx by 1,933.1% in the 4th quarter. Northern Trust Corp now owns 666,845 shares of the company's stock valued at $1,647,000 after acquiring an additional 634,045 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in InflaRx in the 4th quarter valued at $55,000. Walleye Capital LLC acquired a new stake in InflaRx during the 4th quarter worth $51,000. Finally, Commonwealth Equity Services LLC grew its position in InflaRx by 20.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company's stock worth $275,000 after purchasing an additional 19,000 shares during the last quarter. 42.39% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a "buy" rating and issued a $8.00 price objective on shares of InflaRx in a research note on Friday, March 7th.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.